Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Table of Contents | 4 | 8 |
| 1.1 List of Tables | 9 | 1 |
| 1.2 List of Figures | 10 | 2 |
| 2 Introduction | 12 | 1 |
| 2.1 GBI Research Report Guidance | 12 | 1 |
| 3 Global Pharmaceutical Market Overview 2009 | 13 | 4 |
| 3.1 Introduction | 13 | 1 |
| Total Sales Of Pharmaceutical Drugs In 2009 | 13 | 1 |
| 3.3 Market Share By Therapeutic Areas, 2009 | 14 | 1 |
| 3.4 Top Selling Drugs Of 2009 | 15 | 1 |
| 3.4.1 Lipitor (atorvastin) | 15 | 1 |
| 3.4.2 Plavix (clopidrogel) | 15 | 1 |
| 3.4.3 Nexium (esmoprazole) | 15 | 1 |
| 3.4.4 Advair (fluticasone salmetrol) | 15 | 1 |
| 3.4.5 Seroquel (quetiapine) | 15 | 1 |
| 3.4.6 Diovan (valsartan) | 15 | 1 |
| 3.4.7 Enbrel (etanercept) | 15 | 1 |
| 3.4.8 Remicade (infliximab) | 15 | 1 |
| 3.4.9 Crestor (rosuvastatin) | 15 | 1 |
| 3.4.10 Zyprexa (olanzapine) | 15 | 1 |
| 3.5 Key Patent Expirations Of Drugs In 2009 | 16 | 1 |
| 4 Key Therapeutic Landscape | 17 | 65 |
| Cardiovascular Disease Therapeutics | 17 | 1 |
| 4.1.1 Drivers for Cardiovascular Therapeutics Market | 18 | 1 |
| 4.1.1.1 Increase In The Aging Population | 19 | 1 |
| 4.1.1.2 Stable Increase In The Incidence Rates For Cardiovascular Disorders | 19 | 1 |
| 4.1.1.3 Increase In The Diagnosis Rate Of The Disease | 19 | 1 |
| 4.1.1.4 Increase In The Awareness Levels Of Disease Progression And Etiology | 19 | 1 |
| 4.1.2 Restraints For Cardiovascular Therapeutics Market | 20 | 1 |
| 4.1.2.1 Patent Expiries Coupled With Generic Competition | 20 | 1 |
| 4.1.2.2 Presence Of Serious Side Effects | 20 | 1 |
| 4.1.2.3 Reimbursement Restrictions On Patented Drugs | 20 | 1 |
| 4.1.3 Merger And Acquisition Deals Landscape For Cardiovascular Therapeutics, 2009-2010 | 21 | 2 |
| 4.2 Respiratory Disease Therapeutics | 23 | 1 |
| 4.2.1 Drivers For Respiratory Therapeutics Market | 24 | 1 |
| 4.2.1.1 Increase In Aging Population | 25 | 1 |
| 4.2.1.2 Increase In The Incidence Rates For Respiratory Disorders | 25 | 1 |
| 4.2.1.3 Increase In The Diagnosis Rate Of Patients Has Lead To Market Growth | 25 | 1 |
| 4.2.1.4 Increase In Awareness Levels Of Disease Progression And Etiology | 25 | 1 |
| 4.2.2 Restraints For Respiratory Therapeutics Market | 25 | 1 |
| 4.2.2.1 Patent Expiries Of Blockbuster Drugs | 25 | 1 |
| 4.2.2.2 Serious Side Effects For Certain Drugs Have Lead To Non-Initiation And Non Compliance Of The Therapy | 25 | 1 |
| 4.2.2.3 Reimbursement Restrictions On Patented Drugs Has Restricted The Market Growth | 25 | 1 |
| 4.2.3 Merger And Acquisition Deals Landscape For Respiratory Therapeutics, 2009-2010 | 26 | 1 |
| Musculoskeletal Disorder Therapeutics | 27 | 2 |
| 4.3.1 Drivers For Musculoskeletal Therapeutics Market | 29 | 1 |
| 4.3.1.1 Steady Increase In The Elderly Population | 30 | 1 |
| 4.3.1.2 High Incidence And Prevalence Rate Of The Musculoskeletal Disorders | 30 | 1 |
| 4.3.1.3 Increase In Obesity Population | 30 | 1 |
| 4.3.2 Restraints For Musculoskeletal Therapeutics Market | 30 | 1 |
| 4.3.2.1 Poor Diagnosis Rate Of The Disease Due To Lack Of Advanced Techniques | 30 | 1 |
| 4.3.2.2 Low Affordability Of Patients To Get The Treatment For Musculoskeletal Disorders | 30 | 1 |
| 4.3.2.3 Availability Of Alternative Treatment Options | 30 | 1 |
| 4.3.3 Merger And Acquisition Deals Landscape For Musculoskeletal Therapeutics, 2009-2010 | 30 | 2 |
| Oncology Therapeutics | 32 | 2 |
| 4.4.1 Drivers For Oncology Therapeutics Market | 34 | 1 |
| 4.4.1.1 Steady Increase In The Aging Population | 34 | 1 |
| 4.4.1.2 New Innovative Products In The Pipeline | 34 | 1 |
| 4.4.1.3 Rapid Uptake Of Targeted Therapies In Key Cancer Indications | 35 | 1 |
| 4.4.2 Restraints For Oncology Therapeutics Market | 35 | 1 |
| 4.4.2.1 The US Cancer Incidence Moving Towards A Decelerating Growth Rate | 35 | 1 |
| 4.4.2.2 Patent Expirations And Entry Of Generics | 35 | 1 |
| 4.4.3 Merger And Acquisition Deals Landscape For Oncology, 2009-2010 | 36 | 2 |
| 4.5 Central Nervous System Therapeutics | 38 | 2 |
| 4.5.1 Drivers For CNS Therapeutics Market | 40 | 1 |
| 4.5.1.1 Steady Increase In The Aging Population | 40 | 1 |
| 4.5.1.2 Stable Increase In Incidence Rates For CNS Disorders | 40 | 1 |
| 4.5.1.3 Increase In Awareness Levels Of Disease Progression And Etiology | 40 | 1 |
| 4.5.2 Restraints For CNS Therapeutics Market | 41 | 1 |
| 4.5.2.1 Patent Expirations And Entry Of Generics Pose A Serious Problem For Primary Manufacturers | 41 | 1 |
| 4.5.2.2 Presence Of Serious Side Effects For Certain Classes Of Therapeutic Drugs | 41 | 1 |
| 4.5.2.3 Reimbursement Restrictions On Drug Classes For Certain CNS Disorders | 41 | 1 |
| 4.5.3 Merger And Acquisition Deals Landscape For Central Nervous System (CNS) Therapeutics, 2009-2010 | 42 | 1 |
| Autoimmune Disease Therapeutics | 43 | 2 |
| 4.6.1 Drivers For Autoimmune Therapeutics Market | 45 | 1 |
| 4.6.1.1 Increasing Diseased Population | 46 | 1 |
| 4.6.1.2 Increasing Treatment Seeking Behavior Amongst Patients | 46 | 1 |
| 4.6.1.3 Increase In The Usage Of Biologics As A Primary Mode Of Therapy | 46 | 1 |
| 4.6.2 Restraints for Autoimmune Therapeutics Market | 46 | 1 |
| 4.6.2.1 Increase In The Treatment Cost | 46 | 1 |
| 4.6.2.2 Increase In The Entry Of Generics | 46 | 1 |
| 4.6.2.3 Presence Of Serious Side Effects | 46 | 1 |
| 4.6.3 Merger and Acquisition Deals Landscape for Autoimmune Diseases Therapeutics, 2009-2010 | 47 | 1 |
| Gastrointestinal Disorder Therapeutics | 48 | 2 |
| 4.7.1 Drivers For Gastrointestinal Therapeutics Market | 50 | 1 |
| 4.7.1.1 Steady Increase In The Elderly Population | 50 | 1 |
| 4.7.1.2 Stable Increase In The Incidence Rates For Gastrointestinal Disorders | 50 | 1 |
| 4.7.1.3 Increase In Awareness Levels Of Disease Progression And Etiology | 50 | 1 |
| 4.7.2 Restraints For Gastrointestinal Therapeutics Market | 51 | 1 |
| 4.7.2.1 Entry Of Generics Due To Patent Loss Pose A Serious Problem For Primary Manufacturers | 51 | 1 |
| 4.7.2.2 Presence Of Serious Side Effects For Certain Classes Of Therapeutic Drugs | 51 | 1 |
| 4.7.3 Merger And Acquisition Deals Landscape For Gastrointestinal Therapeutics, 2009-2010 | 51 | 2 |
| 4.8 Dermatology Therapeutics | 53 | 2 |
| 4.8.1 Drivers For Dermatology Therapeutics Market | 55 | 1 |
| 4.8.1.1 Steady Increase In The Elderly Population | 55 | 1 |
| 4.8.1.2 Stable Increase In The Incidence Rates For Dermatology Diseases | 55 | 1 |
| 4.8.1.3 Increase In Awareness Levels Of Disease Progression And Etiology | 55 | 1 |
| Restraints For Dermatology Therapeutics Market | 56 | 1 |
| 4.8.2.1 Entries Of Generics Pose A Serious Problem For Primary Manufacturers | 56 | 1 |
| 4.8.2.2 Presence Of Serious Side Effects Of Certain Class Of Therapeutic Drugs | 56 | 1 |
| 4.8.3 Merger And Acquisition Deals Landscape For Dermatology Therapeutics, 2009-2010 | 56 | 1 |
| Opthalmology Therapeutics | 57 | 3 |
| 4.9.1 Drivers For Ophthalmology Therapeutics Market | 60 | 1 |
| 4.9.1.1 Research And Development Activity | 60 | 1 |
| 4.9.1.2 Increase In Awareness Levels Of Disease | 60 | 1 |
| 4.9.1.3 Increase In The Prevalence Of Diabetes | 60 | 1 |
| 4.9.2 Restraints For Ophthalmology Therapeutics Market | 60 | 1 |
| 4.9.2.1 Entry Of Generics Due To Patent Loss | 60 | 1 |
| 4.9.2.2 Entry Of Off-Label Products | 60 | 1 |
| 4.9.3 Merger And Acquisition Deals Landscape For Ophthalmology Therapeutics, 2009-2010 | 61 | 1 |
| Men s Health Therapeutics | 62 | 2 |
| 4.10.1 Drivers for Men s Health Market | 64 | 1 |
| 4.10.1.1 Steady Increase In Prevalence Population | 64 | 1 |
| 4.10.1.2 Launch Of Late Stage Pipeline Drugs | 64 | 1 |
| 4.10.1.3 Steady Increase In The Prescription Population | 64 | 1 |
| 4.10.2 Restraints for Men s Health Market | 65 | 1 |
| 4.10.2.1 Low Treatment Seeking Rate | 65 | 1 |
| 4.10.2.2 Low Diagnosis Rate | 65 | 1 |
| 4.10.2.3 Patent Expiry Of A Major Blockbuster Drug | 65 | 1 |
| 4.10.3 Merger And Acquisition Deals Landscape For Men s Health Therapeutics, 2009-2010 | 65 | 1 |
| Women s Health Therapeutics | 66 | 2 |
| 4.11.1 Drivers For Women s Health Market | 68 | 1 |
| 4.11.1.1 Introduction Of First In Class Therapies With Better Efficacy | 68 | 1 |
| 4.11.1.2 Increase In Aging Population | 68 | 1 |
| 4.11.1.3 Increase In Treatment Seeking Population Due To Awareness | 68 | 1 |
| 4.11.2 Restraints For Women s Health Market | 69 | 1 |
| 4.11.2.1 Availability Of Alternative Treatment Options Such As Yoga, Physiotherapy And Others | 69 | 1 |
| 4.11.2.2 Low Prescription Rate Due To Unclear Etiology | 69 | 1 |
| 4.11.3 Merger And Acquisition Deals Landscape For Women s Health Therapeutics, 2009-2010 | 69 | 1 |
| Blood Disorders Therapeutics | 70 | 2 |
| 4.12.1 Drivers For Blood Disorders Therapeutics | 72 | 1 |
| 4.12.1.1 Increase In The Prevalence Population Particularly In Anemia, In The Top Five Countries In Europe | 72 | 1 |
| 4.12.1.2 Rapid Uptake Of Biologics Products Due To Better Efficacy And Safety | 72 | 1 |
| 4.12.1.3 Increase In Blood Disorders Causing Conditions Such As Cancer And Cardiovascular Events | 72 | 1 |
| 4.12.2 Restraints For Blood Disorders Therapeutics | 73 | 1 |
| 4.12.2.1 Patent Expiries Of Major Blockbuster Drugs | 73 | 1 |
| 4.12.2.2 Low Diagnosis Rate As The Contemporary Diagnostic Tools Are Unable To Diagnose The Severe Forms Of Blood Disorders | 73 | 1 |
| 4.12.2.3 Sluggish Growth In Annual Cost Of Therapy For Blood Disorders | 73 | 1 |
| 4.12.3 Merger And Acquisition Deals Landscape For Blood Disorders Therapeutics Market, 2009-2010 | 74 | 2 |
| 4.13 Urological Therapeutics Market | 76 | 2 |
| 4.13.1 Drivers For Urology Therapeutics | 78 | 1 |
| 4.13.1.1 Steady Increase In The Prevalence Population | 78 | 1 |
| 4.13.1.2 Rapid Uptake Of Branded Products Due To Better Efficacy In BPH | 78 | 1 |
| 4.13.1.3 Patent Expiry Of Branded Drugs Will Make Them More Affordable | 78 | 1 |
| 4.13.2 Restraints for Urology Therapeutics Market | 79 | 1 |
| 4.13.2.1 Unwillingness To Seek Medical Help For UI | 79 | 1 |
| 4.13.2.2 Patent Expiry Of Major Blockbuster Drugs | 79 | 1 |
| 4.13.2.3 Non-Pharmacological Therapy Recommended For BPH And UI | 79 | 1 |
| 4.13.3 Merger And Acquisition Deals Landscape For Urology Therapeutics, 2009-2010 | 80 | 2 |
| 5 Key Promising Drugs In The Pipeline | 82 | 53 |
| 5.1 Cardiovascular Therapeutics | 82 | 1 |
| 5.1.1 Tekturna/Rasilez (acute heart failure) | 82 | 1 |
| 5.1.1.1 Overview | 82 | 1 |
| 5.1.1.2 Efficacy | 82 | 1 |
| 5.1.1.3 Safety | 82 | 1 |
| 5.1.1.4 Clinical Study Details | 82 | 1 |
| 5.1.2 Lixivaptan (acute heart failure) | 83 | 1 |
| 5.1.2.1 Overview | 83 | 1 |
| 5.1.2.2 Efficacy | 83 | 1 |
| 5.1.2.3 Safety | 83 | 1 |
| 5.1.2.4 Clinical Study Details | 83 | 1 |
| 5.1.3 Relaxin (acute heart failure) | 83 | 1 |
| 5.1.3.1 Overview | 83 | 1 |
| 5.1.3.2 Efficacy | 83 | 1 |
| 5.1.3.3 Safety | 84 | 1 |
| 5.1.3.4 Clinical Study Details | 84 | 1 |
| 5.1.4 Cinaciguat (acute heart failure) | 84 | 1 |
| 5.1.4.1 Overview | 84 | 1 |
| 5.1.4.2 Efficacy | 84 | 1 |
| 5.1.4.3 Safety | 84 | 1 |
| 5.1.4.4 Clinical Study Details | 84 | 1 |
| 5.1.5 Xarelto (atrial fibrillation) | 85 | 1 |
| 5.1.5.1 Overview | 85 | 1 |
| 5.1.5.2 Efficacy | 85 | 1 |
| 5.1.5.3 Safety | 85 | 1 |
| 5.1.5.4 Clinical Study Details | 85 | 1 |
| 5.1.6 Pradaxa (atrial fibrillation) | 86 | 1 |
| 5.1.6.1 Overview | 86 | 1 |
| 5.1.6.2 Efficacy | 86 | 1 |
| 5.1.6.3 Safety | 86 | 1 |
| 5.1.6.4 Clinical Study Details | 86 | 1 |
| 5.1.7 Stedicor (atrial fibrillation) | 86 | 1 |
| 5.1.7.1 Overview | 86 | 1 |
| 5.1.7.2 Efficacy | 86 | 1 |
| 5.1.7.3 Safety | 86 | 1 |
| 5.1.7.4 Clinical Study Details | 87 | 1 |
| 5.1.8 Kynapid (atrial fibrillation) | 87 | 1 |
| 5.1.8.1 Overview | 87 | 1 |
| 5.1.8.2 Efficacy | 87 | 1 |
| 5.1.8.3 Safety | 88 | 1 |
| 5.1.8.4 Clinical Study Details | 88 | 1 |
| 5.1.9 Edoxaban (atrial fibrillation) | 88 | 1 |
| 5.1.9.1 Overview | 88 | 1 |
| 5.1.9.2 Efficacy | 88 | 1 |
| 5.1.9.3 Safety | 88 | 1 |
| 5.1.9.4 Clinical Study Details | 88 | 1 |
| 5.2 Respiratory Therapeutics | 89 | 1 |
| 5.2.1 Flutiform (fluticasone propionate/formoterol fumarate inhalation aerosol) (asthma) | 89 | 1 |
| 5.2.1.1 Overview | 89 | 1 |
| 5.2.1.2 Efficacy | 89 | 1 |
| 5.2.1.3 Safety | 89 | 1 |
| 5.2.1.4 Clinical Study Details | 89 | 1 |
| 5.2.2 MFF 258 (Mometasone furoate/formoterol fumarate) (asthma) | 90 | 1 |
| 5.2.2.1 Overview | 90 | 1 |
| 5.2.2.2 Efficacy | 91 | 1 |
| 5.2.2.3 Safety | 91 | 1 |
| 5.2.2.4 Clinical Study Details | 91 | 1 |
| 5.2.3 Aclidinium bromide (Chronic Obstructive Pulmonary Disease-COPD) | 91 | 1 |
| 5.2.3.1 Overview | 91 | 1 |
| 5.2.3.2 Efficacy | 91 | 1 |
| 5.2.3.3 Safety | 91 | 1 |
| 5.2.3.4 Clinical Study Details | 91 | 1 |
| 5.2.4 GW642444 ( 444) (COPD) | 92 | 1 |
| 5.2.4.1 Overview | 92 | 1 |
| 5.2.4.2 Efficacy | 92 | 1 |
| 5.2.4.3 Safety | 92 | 1 |
| 5.2.4.4 Clinical Study Details | 92 | 1 |
| 5.2.5 Iloprost (Pulmonary Arterial Hypertension) | 93 | 1 |
| 5.2.5.1 Overview | 93 | 1 |
| 5.2.5.2 Efficacy | 93 | 1 |
| 5.2.5.3 Safety Profile | 93 | 1 |
| 5.2.5.4 Clinical Study Details | 93 | 1 |
| 5.2.6 ACT-064992 (Pulmonary Arterial Hypertension) | 93 | 1 |
| 5.2.6.1 Overview | 93 | 1 |
| 5.2.6.2 Efficacy | 93 | 1 |
| 5.2.6.3 Safety Profile | 93 | 1 |
| 5.2.6.4 Clinical Study Details | 93 | 1 |
| 5.2.7 Denufosol Tetrasodium Inhalation Solution (INS37217) (Cystic Fibrosis) | 94 | 1 |
| 5.2.7.1 Overview | 94 | 1 |
| 5.2.7.2 Efficacy | 94 | 1 |
| 5.2.7.3 Safety | 94 | 1 |
| 5.2.7.4 Clinical Study Details | 94 | 1 |
| 5.2.8 VX-770 (Cystic Fibrosis) | 95 | 1 |
| 5.2.8.1 Overview | 95 | 1 |
| 5.2.8.2 Efficacy | 95 | 1 |
| 5.2.8.3 Safety | 95 | 1 |
| 5.2.8.4 Clinical Study Details | 95 | 1 |
| 5.3 Musculoskeletal Disorder Therapeutics | 96 | 1 |
| 5.3.1 Catena/Sovrima (Idebenone) | 96 | 1 |
| 5.3.1.1 Overview | 96 | 1 |
| 5.3.1.2 Efficacy | 96 | 1 |
| 5.3.1.3 Safety | 96 | 1 |
| 5.3.1.4 Clinical Study Details | 96 | 1 |
| 5.3.2 IPlex(TM) (mecasermin rinfabate) | 96 | 1 |
| 5.3.2.1 Overview | 96 | 1 |
| 5.3.2.2 Efficacy | 96 | 1 |
| 5.3.2.3 Safety | 96 | 1 |
| 5.3.2.4 Clinical Study Details | 96 | 1 |
| 5.3.3 CG5503 | 97 | 1 |
| 5.3.3.1 Overview | 97 | 1 |